Black Diamond Expects Cash To Last Into 2028 As It Plans Brain-Metastases Trial
Silevertinib produced an 86% brain-tumor response rate among seven evaluable patients; a controlled late-stage trial is planned.
Black Diamond Therapeutics, which is testing the oral cancer drug silevertinib in lung cancer and glioblastoma, expects its approximately $102.0 million in cash and investments to fund operations into the second half of 2028. The balance fell from $128.7 million at year-end, according to the earnings release accompanying Tuesday's SEC filing, as the company outlined a planned late-stage lung-cancer trial focused on patients with brain metastases.
Seven Patients Anchor Brain-Tumor Results
Updated silevertinib data showed an 86% response rate in brain tumors among seven evaluable patients. They were part of a 16-patient group whose lung cancer had spread to the brain and whose brain metastases were untreated; that group's median time without overall disease progression was 12.2 months.
The mid-stage study treated 43 previously untreated lung-cancer patients with non-classical mutations in EGFR, the epidermal growth factor receptor gene. Across the study, 60% had a tumor response, 93% had disease controlled, and the median time without progression was 15.0 months.
Among 24 patients without brain metastases, median time without progression reached 23.5 months, and none had progression in the brain. At the October 7 data cutoff, median follow-up was 15.9 months; 18 patients were still receiving treatment, the longest for 26.2 months. The study used a 200-milligram daily dose, and no new safety concerns were observed.
Those findings come from a study without a comparison group. Black Diamond cautioned that differences between studies limit comparisons with other drugs; these results cannot establish superiority.
A Controlled Test For Approval
Black Diamond had already said Monday that FDA feedback supported a potential accelerated-approval route. Tuesday's update detailed a global late-stage trial that would assign 300 patients with untreated brain metastases equally to silevertinib or a physician's choice of osimertinib or afatinib.
The company plans separate, uncontrolled groups of 80 patients without brain metastases and 20 with leptomeningeal disease. Brain-tumor response assessed by independent reviewers would support potential accelerated approval; time without overall disease progression would support potential full approval. The FDA also wants evaluation of overall tumor response and survival against the comparison treatment.
Black Diamond President and CEO Mark Velleca said, “This trial design offers a differentiated path to potential accelerated approval in EGFR-NCM patients, who represent about 25% of the frontline EGFR mutant patient population.”
Before opening that trial, Black Diamond must submit sufficient safety data for the proposed 150-milligram daily dose. A 20-patient group is enrolling at that dose, with its first patient treated in the third quarter. Management sees a possible trial start in the second quarter of 2027 and anticipates preliminary results in 2028 if that schedule holds.
Spending And The Glioblastoma Program
Third-quarter net loss widened to $10.0 million, or $0.17 per share, from $8.5 million, or $0.15 per share, a year earlier. Operating cash use increased to $8.3 million from $7.9 million.
Administrative costs rose to $5.1 million from $3.5 million, which Black Diamond attributed primarily to intellectual-property costs and higher non-income taxes. Research spending fell to $7.0 million from $7.4 million; the company tied that decline mainly to lung-cancer trial progression, partly offset by glioblastoma trial costs.
More than 200 patients across lung cancer and glioblastoma have received silevertinib. The randomized portion of its mid-stage study in newly diagnosed EGFRvIII-positive glioblastoma is enrolling at 150 milligrams daily, with the first patient treated in the fourth quarter. Six patients received that dose with temozolomide during the completed safety run-in, with no dose-limiting toxicities observed.
Black Diamond expects interim results measuring time without progression in the glioblastoma trial in the first half of 2028.
Sources
- 8-K Filing — Black Diamond Therapeutics, Inc. (BDTX) — SEC EDGAR
- Exhibit bdtx-exhibit991_q32026.htm — Black Diamond Therapeutics, Inc. 8-K exhibit — SEC EDGAR
- Black Diamond Therapeutics to Host Webcast Highlighting Updated Silevertinib Phase 2 Data and FDA Feedback Supporting a Clear Phase 3 Path to Potential Accelerated Approval in 1L EGFR-NCM NSCLC — Yahoo Finance
- Black Diamond Therapeutics to Host Webcast Highlighting — globenewswire.com